Denali Therapeutics logo

Denali Therapeutics

DNLI | NASDAQ
Chart Builder DCF Calculator
$18.08
-$0.66 (-3.52%)
At close: Nov 16, 2026, 4:00 PM ET
$18.08
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.52%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
37.4
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #600/1021 (Top 59%)

Key Statistics

Market Data

Market Cap $3.41B
1D Range
18.08 18.87
52W Range
16.02 27.21

Valuation (TTM)

PE -10.45
PB 3.68
EV/EBITDA -5.81

Valuation (NTM)

Forward PE N/A
Forward PEG 0.27
Price Target $34.00
Loading financial charts...

Profile

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditio...

Sector Healthcare
Industry Biotechnology
Employees 503
IPO Date Dec 8, 2017
Fiscal Year January - December

Latest News

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

3 days ago · seekingalpha.com

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)

3 days ago · seekingalpha.com

Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near

3 days ago · marketbeat.com

Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

11 days ago · zacks.com

DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
Denali Therapeutics Q3 Earnings Call Highlights

13 days ago · marketbeat.com

Denali Therapeutics Q3 Earnings Call Highlights
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates

13 days ago · zacks.com

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

18 days ago · globenewswire.com

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

25 days ago · globenewswire.com

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Earnings

Latest Earnings
Nov 3, 2026
EPS
$0.37
Beat +236.56%
REV
$17.78M
Beat +40.28%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$34.00
Upside
+88.05%
Buy (11)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.